Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CTIM-76

Bispecific antibody · Immune activation, directed at claudin 6 (CLDN6) and CD3 (CD3D) · developed by Context Therapeutics

Phase 1 Most advanced trial
CNTX Developer
1 Registered trials

What is CTIM-76?

CTIM-76 is an Fc-silenced humanized IgG1 bispecific antibody that binds claudin 6 on tumor cells and CD3 on T cells, redirecting cytotoxic T lymphocytes to kill CLDN6-expressing tumors. It is studied in platinum-resistant ovarian, testicular, and endometrial cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
claudin 6 (CLDN6), CD3 (CD3D)
Mechanism
Immune activation, directed at claudin 6 (CLDN6) and CD3 (CD3D)
Pathways
T-cell activation, cytotoxic T-lymphocyte-mediated killing
Therapy area
Oncology
Developer
Context Therapeutics Inc. (CNTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06515613 Phase 1 Platinum-resistant Ovarian Cancer Recruiting CNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endometrial CancerPlatinum-resistant Ovarian CancerTesticular Cancer

Other drugs acting on CLDN6 / CD3D

Tarlatamab FDA approved Xaluritamig Phase 3 ZW171 Phase 1

More from Context Therapeutics

CT-202 Phase 1 CT-95 Phase 1 Onapristone Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CNTX page.

Follow CNTX, the company behind CTIM-76

See CNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CNTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.